The DNA ligase 1 (LIG1) antibody is a critical tool for studying LIG1. an enzyme essential for DNA replication and repair. LIG1 catalyzes the final step in DNA synthesis by sealing nicks between Okazaki fragments during replication and repairing single-strand breaks in base excision repair. Dysregulation of LIG1 is linked to genome instability, cancer susceptibility, and rare genetic disorders like LIG1 deficiency syndrome, characterized by immunodeficiency and developmental delays.
LIG1 antibodies are widely used in molecular biology to detect and quantify LIG1 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help investigate LIG1's role in DNA repair pathways, cell cycle regulation, and its interaction with other repair proteins (e.g., PCNA). Researchers also utilize these antibodies to explore correlations between LIG1 expression and clinical outcomes, such as chemotherapy resistance in tumors or disease progression in neurodegenerative conditions.
Recent studies highlight LIG1's potential as a biomarker for cancer prognosis and a therapeutic target. Its antibody is pivotal in elucidating mechanisms of DNA damage response, replication stress, and genomic maintenance. By enabling precise localization and functional analysis, LIG1 antibodies advance our understanding of cellular responses to genotoxic agents and inform strategies for targeted therapies in oncology and genetic disorders.